NEWS
We sold N-vision 3D endoscopy to NeuroSpineClinic.Prince of Wales Private Hospital.
We sold N-vision 3D endoscopy to NeuroSpineClinic.Prince of Wales Private Hospital,Randwick.Sydney Australia.(
Press Release “Notice of Commencement of Multi-institutional Joint Research on quasi-3D fluoroscopic images using AI Technology”
Notice of Commencement of Multi-institutional Joint Research on quasi-3D fluoroscopic images using AI Technolo
Published in AP news”World’s First 3D Medical Image Conversion Technology”
【Event】SOSV Health Tech Matchup – Feb 26-Mar 8, 2024
we’ve been approved for participation of 2024 Health Tech VC-Founder Matchup. What is SOSV Health Tech M
Happy new year 2024
To all, Happy New Year! As we embark on a new year, it is the season to take new steps with renewed hearts. We
We will talk a Lightning Talk at KLSAP2023
About The Kansai Life Science Accelerator Program (KLSAP) was launched in 2020 to provide Japanese startups wi
We sold N-vision 3D endoscopy to NeuroSpineClinic.Prince of Wales Private Hospital.
We sold N-vision 3D endoscopy to NeuroSpineClinic.Prince of Wales Private Hospital,Randwick.Sydney Australia.
(Use in Research)
Areas of Practice:Neurosurgery
Press Release “Notice of Commencement of Multi-institutional Joint Research on quasi-3D fluoroscopic images using AI Technology”
Notice of Commencement of Multi-institutional Joint Research on quasi-3D fluoroscopic images using AI Technology
This announcement has been officially approved by the public relations of NCC (National Cancer Center Hospital) and Asahi General Hospital
Novius Company, ltd is pleased to announce that it has signed off the multi-institutional joint research agreement with NCC (National Cancer Center Hospital) and Asahi General Hospital, the research started on April 1, 2024.
<Title of Research>
The multi-institutional observational study on quasi-3D of fluoroscopic images using AI technology.
<Research Overview>
The objective of this research is to enable real-time recognition of the “front” and “back” of flat fluoroscopic image by converting it
to quasi-3D, thereby facilitating guidance to the lesion. We will also continue research and development on the 3Dization of planar images using biplane angiography system at the same time.
<Planned research person who applies>
Patients who underwent bronchoscopy at the National Cancer Center Hospital. Patients who underwent an examination using a biplane angiography device or x-ray fluoroscopy device at the NCC Hospital and Asahi Center Hospital
<Term of Study>
April 1, 2024, to March 31, 2028
<Research Background>
Conventional bronchoscopy biopsy using only x-ray fluoroscopy has an inadequate diagnostic yield because of uncertainty in assessing whether the biopsy instrument has reached the lesion due to difficulty in grasping the three-dimensional positioning of the lesion. The reason for this is that the image depicted by fluoroscopy is two-dimensional, and at least the frontal image alone is not suitable for understanding anterior-posterior misalignment and distance.
<Future Prospects with Technologies to be Researched and Developed>
Real-time 3D fluoroscopic images using AI x 3D conversion technology,
By using AI x 3D conversion technology to convert fluoroscopic images into real-time 3D image
・The location and orientation of catheters in the body can be visualized in more detail and with greater accuracy.
・Real-time 3D images enable physicians to visualize the relationship between the catheter and surrounding tissue in three dimensions.
The real-time 3D image allows physicians to visualize the relationship between the catheter and surrounding tissues in three dimensions,
and to evaluate the catheter appropriately based on these images, thereby improving the accuracy and safety of bronchoscopy.
In cardiovascular procedures, real-time 3D images enhance visualization of complex cardiac anatomy and can guide interventions such as
coronary angioplasty and stent placement.
<Title of Research>
The Multi-institutional observational study on quasi-3D of fluoroscopic images using AI technology
<Research Implementation Structure>
(Leader of Research Project and Principal Researcher)
Yuji Matsumoto MD
Department of Endoscopy (Respiratory Organs),
National Cancer Center Hospital
(Principal Researcher)
Jun Isobe MD, Chief Radiologist & General Manager of Department of Radiology,
Asahi General Hospital
(Principal Researcher)
Koji Okawa, Chief Architect of AI Development
Novius Company,ltd
(Research Administration Office)
Yukihiro Yoshida,MD, Department of Pulmonary Surgery,
National Cancer Center Hospital
Postal code 104-0045
Address: 5-1-1 Tsukiji, Chuo-Ku, Tokyo, Japan
TEL: 03-3542-2511
Published in AP news”World’s First 3D Medical Image Conversion Technology”
Published in AP NEWS
The following Original URL ::
Japanese Startup ‘Novius’ Launches World’s First 3D Medical Image Conversion Technology
AI-powered glass-free monitor converts 2D medical scans to 3D in real-time enhancing
diagnostics, treatment planning, and therapeutic outcomesTOKYO, JAPAN – MAY 7, 2024 – Novius today announced the launch of its innovative new AI-driven
technology, N-Vision 3D, which converts imagery from two-dimensions to three-dimensions in real time
to elevate the way surgery is performed. N-Vision 3D has the potential to revolutionize imaging for
endoscopes, X-ray fluoroscopy equipment, and angiography because existing 2D endoscopes (monocular
camera) can still be used with N-Vision 3D without any modifications. N-Vision 3D works without any
eye-tracking technology and it’s possible to share the imagery with multiple audiences, not just one
person who is wearing goggles, for example. The Novius-designed 3D monitor is its proprietary glass-free
monitor that visualizes 3D imagery without the need for users to wear any glasses or other equipment.
While 3D technology has previously relied on eye-tracking technology and has long been used in the
United States, N-Vision 3D functions differently and provides unique benefits. Novius has achieved the
world’s fastest conversion speed through its proprietary AI technology combined with NVIDIA GeForce
RTX graphics cards. The glass-free technology can convert video from 2D to 3D in just 0.008 seconds,
depending on the environment. The conversion of 2D medical scans into precise, interactive 3D models
enables enhanced diagnostics, treatment planning, and therapeutic outcomes, positioning it to
revolutionize healthcare.
“We are thrilled to introduce N-Vision 3D to the American market, where we believe it can greatly
enhance the capabilities of surgical procedures. This technology is a new perspective on surgery because
modern medical 3D technology is 3DCG or 3D animation, whereas our technology works differently by
combining AI, real-time, and 3D technologies,” said Tomoko Fujino, CEO and Founder, Novius.
“Leveraging the power of artificial intelligence, N-Vision 3D will facilitate diagnosis and the
understanding of lesions that require stereoscopic interpretation and contribute to improved surgical
procedures.”
The usefulness of N-Vision 3D goes beyond hypotheticals, as Novius has already begun using N-Vision 3D
technology for X-ray fluoroscopes and angiographies with real patients in Japan. The installation of NVision 3D to existing endoscopy procedures is simple and can be done by a doctor or an assistant. New software installation, additional hardware peripherals, or modifications by the manufacturer are not necessary.N-Vision 3D (Endoscopy) packages include the following:
Novius Glass-Free 19-inch 3D monitor (you can use 3D displays already on the market, some
products are not matched/LFD display)N-Vision 3D softwareHDMI cable and operation manual<
NVIDIA GPU-installed GeForce RTX desktop or GeForce RTX notebook computer
Capture card and one-year warranty
N-Vision 3D creates a sense of depth that is almost palpable. The unique curved videoscope enables a
more accurate spatial understanding, which has been difficult with conventional endoscope systems. The
entire image of the observed object emerges as vividly as in an open surgery. Endoscopic and
laparoscopic surgery can be performed more precisely and more rapidly. N-Vision 3D can be particularly
beneficial for doctors and researchers.
N-Vision 3D technology has been confirmed by Japan’s Ministry of Health in Japan as a programmed
medical device and a non-medical device. It is intended for use in the medical field as an AI image
support system, or in the case of this technology, for data display, storage, and transfer processing. In
2021, Novius’ patent-pending “real-time video conversion technology” was certified as part of the
NVIDIA Inception Partner program. Novius is also a certified Intel® Alliance Partner.
Novius technology has been utilized as part of a joint research project between Novius and Japan’s
National Cancer Center. The objective of the project is to improve the accuracy of diagnosis by using AI
technology to convert 2D fluoroscopic images of lesions into 3D in real-time, enabling the recognition of
the front or back of the image and facilitating the guidance of the bronchoscope to the lesion. The end
goal is to enable patients to undergo surgery sooner. In 2023, Novius was selected as one of 10
Finalists for the 31st General Assembly of the Japanese Association of Medical Sciences
exposition.
Novius’ proprietary AI-based technology has the potential to be transformative not only in the
medical field but also in entertainment, smartphones, security, drones, geophysics, and several other
industries.
Novius founder and CEO, Tomoko Fujino, can be made available for select Zoom-based video interviews
with media outlets in the United States or in-person and on-camera interviews with outlets in Japan.
Novius’ N-Vision 3D is available now with pricing and more information available at
https://novius.co.jp/en/. Novius is also seeking investors for its latest funding round.
About Novius: Novius, Inc. was founded in 2016 in Tokyo, Japan by Ms. Tomoko Fujino. Its mission is to
pioneer advanced AI solutions that rapidly transform 2D medical images into accurate 3D
representations, facilitating quicker and more comprehensive insights for healthcare professionals.
Committed to improving patient care, Novius strives to provide an accessible, high-fidelity 3D medical
imaging system, that can augment diagnostics, treatment decisions, and surgical interventions in real-
time. Novius’ goal in the medical field is real-time simulation by using information obtained from
angiography, CT, and MRI scans.
【Event】SOSV Health Tech Matchup – Feb 26-Mar 8, 2024
we’ve been approved for participation of 2024 Health Tech VC-Founder Matchup.
What is SOSV Health Tech Matchup?
Based on our past experience conducting matchups, we expect that this virtual event will bring together 500 startups and 300 investors for 1:1 meetings online over two weeks, scheduled at mutually convenient times.
In 2023, SOSV Matchups generated over 5,000 one-on-one meetings in Health Tech, Climate and Industrial Tech, receiving high praise from over 2,000 participants:
“6 months of deal flow in a week” (investor)
“Right stage and areas. High quality meetings.” (investor)
“The most value we’ve ever received.” (startup)
“More VC meetings in a week than in the past 6 months.” (startup)
Happy new year 2024
To all, Happy New Year! As we embark on a new year, it is the season to take new steps with renewed hearts. We express our gratitude for the past and, with expectations for the future, we kindly ask for your continued support in the coming year.
We have had a fulfilling year, thanks to all of you. We deeply appreciate the support and cooperation of our customers and business partners, which have made this possible.
In the coming year, we pledge to work even harder for evolution and growth. We will strive to provide valuable services and products to our customers, and we look forward to your continued patronage.
Thank you for your unwavering support. Wishing you a wonderful year ahead.
Tomoko Fujino/CEO
We will talk a Lightning Talk at KLSAP2023
About
The Kansai Life Science Accelerator Program (KLSAP) was launched in 2020 to provide Japanese startups with an online acceleration program by the U.S. accelerator California Life Sciences (CLS) to support their overseas business development.
The KLSAP was launched in 2020 to provide an online acceleration program for Japanese startups by the U.S. accelerator California Life Sciences (CLS) to support global business development.
The 4th KLSAP, will host a pitch competition among 10 companies for only 3 opportunities to participate in the accelerator program. Please come and watch the excited pitches of the companies live.